[17] CHAPTER VIII LESSON 1 Flashcards

1
Q

can be defined as the use of serologic principles and tests to ensure compatibility and prevent an immune-mediated hemolytic transfusion reaction.

A

Pretransfusion testing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

defines blood components as pharmaceuticals because of the intent of their use to cure, mitigate, treat, or prevent disease.

A

Food and Drug Administration (FDA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Under the auspices of the [?], the Centers for Medicare and Medicaid (CMS) have the authority to regulate pretransfusion testing.

A

Clinical Laboratory Improvement Amendments of 1988 (CLIA ’88)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Facilities providing blood components and laboratory services are subject to. [?] by either entity at any given time.

A

inspections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

In addition to maintaining regulatory compliance, many facilities participate in quality driven programs to achieve [?].

A

accreditation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

The [?], now known simply as AABB, is an accrediting organization whose goals include enhancing the quality and safety of services provided by blood banks and transfusion services.

A

American Association of Blood Banks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Adequate pretransfusion testing does not guarantee [?] in the recipient’s circulation, but strict adherence to all facets of pretransfusion testing and donor unit selection is imperative to ensure safe transfusion therapy.

A

normal survival of transfused red blood cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

STEPS IN PRETRANSFUSION TESTING
1. Request for[?]
2. Identification of [?] and blood specimen collected
3. Testing of transfusion recipient’s [?]
4. Donor [?]
5. Donor [?]
6. [?] (crossmatch)
7. Labeling of [?] with the recipient’s identifying information and issue.

A

transfusion

transfusion recipient

blood specimen

RBC unit testing

red blood cell unit selection

Compatibility testing

blood or blood components

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Testing of transfusion recipient’s blood specimen:
a. Evaluation of specimen for testing [?]
b. [?]
c. [?] (Weak D testing is optional when testing the patient)
d. Screening for [?] to red cell antigens
e. [?] if unexpected antibodies are detected
f. Comparison of [?], and any discrepancies shall be investigated and appropriate action taken before a unit is issued for transfusion

A

suitability

ABO group

Rh type

unexpected antibodies

Antibody identification

current and previous test results

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q
  1. Donor RBC unit testing:
    a. ABO group confirmation and Rh type confirmation for [?]
A

Rh-negative RBC units

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q
  1. Donor red blood cell unit selection:
    a. Selection of components of ABO group and Rh type that are compatible with the transfusion recipient and with any [?]
A

unexpected allogeneic antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q
  1. Compatibility testing (crossmatch):
A

a. Serologic
b. Computer or electronic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

SPECIMEN COLLECTION

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Clerical errors and [?] continue to occur and have potentially serious, clinical consequences.

A

ABO-incompatible transfusions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q
  • greatest threat to safe transfusion therapy
A

Clerical error

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Clerical error Examples:
-misidentification of the recipient when the [?] is drawn
-[?] during handling in the laboratory
-misidentification of the recipient when the [?] is given

A

blood sample

mix-up of samples

transfusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Errors include

A

phlebotomy and testing errors, administration to the wrong recipient, or issuance of the wrong donor unit.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

continue to be a significant risk necessitating system to prevent failures in patient identification, specimen labeling, and administration.

A

Transfusion errors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

In order to prevent patient misidentification and administration failures, most institutions require patients to wear a [?] upon admission until discharge

A

facility-generated ID wristband

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

facility-generated ID wristband must contain two unique identifiers, typically the

A

patient’s first and last names and date of birth or medical record number

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

require two unique identifiers to identify patients and ensure that correct medicine and treatment are administered.

A

Joint Commission’s National Patient Safety Goals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Prior to specimen collection, the phlebotomist must confirm the [?] is accurate and contains all required information.

A

wristband information

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Common practice includes asking the patient to state his or her[?], if they are coherent.

A

name and date of birth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Once collected, the specimen must be accurately [?] at the bedside.

A

labeled

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Patient information on the [?] must be in complete agreement.

A

label, wristband, and request

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Furthermore, specimen draw [?] and the collecting individual must be traceable back to the collection of the patient sample.

A

date and time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

are acceptable for pretransfusion testing.

A

Anticoagulated or clotted specimens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

are often preferred due to ease of handling.

A

Anticoagulated specimens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

are ideal for preparing a uniform cell suspension for testing.

A

Red blood cells from an anticoagulated sample

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

may require additional washing steps to minimize interference in test interpretations.

A

Clotted red blood cells

31
Q

is unacceptable, and the use of hemolyzed samples should be avoided.

A

Intravenous line (IV) contamination

32
Q

Specimens should be collected from the arm [?] the IV catheter and never [?] it.

A

opposite

above

33
Q

If venous access is limited and the specimen must be collected from the IV line, the [?]must be stopped and the line flushed.

A

infusion fluid

34
Q

It is recommended that an amount of blood equal to[?] the dead space of the catheter be discarded.

A

three or more times

35
Q

The date of the collection is considered day 0, and the specimen expires at [?].

A

midnight on day 3

36
Q

For example, if a specimen was collected on a Monday (day 0), it may be used for transfusion on Tuesday (day 1), Wednesday (day 2), and [?].

A

Thursday (day 3) until 11:59 p.m

37
Q

The [?] minimizes the risk of an adverse reaction due to an emerging alloantibody in a recipient that has been recently transfused.

A

3-day testing window

38
Q

Pretransfusion specimens and donor unit segments are typically stored at [?] and must be retained in the event that additional testing is warranted.

A

2° to 8°C

39
Q

The patient sample and a segment from the donor unit must be retained post-transfusion for at least [?].

A

7 days

40
Q

are performed to prevent an immune-mediated hemolytic transfusion reaction.

A

Compatibility tests

41
Q

Compatibility tests include: determining the recipient’s [?], screening for any [?], and [?] the donor unit with the recipient’s plasma.

A

ABO group and Rh type

unexpected antibodies

crossmatching

42
Q

Current results such as ABO group and Rh type, detection of clinically significant antibodies, significant adverse events, and special transfusion requirements must be compared to historical records.

A

Review of Records

43
Q

For patients with no historical records, many facilities have implemented an additional specimen draw for a blood type confirmation.

A

Review of Records

44
Q

Any discrepancy between historical records and current test results must be resolved prior to transfusion.

A

Review of Records

45
Q

ABO grouping, Rh typing, and screening for unexpected antibodies must be performed within 3 days prior to the scheduled transfusion except in the previously mentioned situations for which the pretransfusion testing window may be extended.

A

Recipient Testing

46
Q

requires licensed reagents and can be performed using tubes, column-agglutination technology, or in microtiter plates used in solid-phase red cell adherence tests.

A

ABO grouping

47
Q

Required reagents include anti-A and anti-B for detecting the antigens on the red blood cells and A1 and B cells for confirming the naturally occurring antibodies in the plasma.

A

ABO grouping

48
Q

is performed to detect the presence or absence of the D antigen.

A

Rh Typing

49
Q

Licensed anti-D reagents are monoclonal blends of IgM and IgG components.

A

Rh Typing

50
Q

In addition, an Rh control must be tested in parallel with anti-D reagent in the indirect antiglobulin test for weak D determination.

A

Rh Typing

51
Q

The test for weak D is optional in transfusion recipients but is required for donor units during manufacturing.

A

Rh typing

52
Q

Antibodies to blood group antigens must be detected and their clinical significance assessed.

A

Antibody Screening

53
Q

Clinically significant antibodies have been associated with red blood cell destruction, hemolytic transfusion reactions, and hemolytic disease of the fetus and newborn (HDFN).

A

Antibody Screening

54
Q

The FDA mandates that red blood cells used in antibody detection tests must express the following antigens:

A

D, C, E, c, e, K, k, Fya, Fyb, Jka, Jkb, Lea, Leb, P1, M, N, S, and s.

55
Q

A common goal shared by blood suppliers and transfusion services is to provide a safe and efficacious blood component that benefits the intended recipient.

A

SELECTION OF DONOR UNITS

56
Q

Blood suppliers are required to perform a battery of tests on blood components prior to distribution

A

Donor Unit Testing

57
Q

Tests performed are ABO grouping, Rh typing, a weak D test if the initial Rh typing result is negative, and a screen for antibodies to common blood group antigens.

A

Donor Unit Testing

58
Q

Required infectious disease testing on donor units includes HBV DNA, HBsAG, HBc antibodies, HCV antibodies, HCV RNA, HIV1/2 antibodies, HIV-1 RNA, HTLV I/II antibodies, WNV RNA, and a serologic test for syphilis.

A

Donor Unit Testing

59
Q

In addition, each donor must be tested at least once for antibodies to Trypanosoma cruzi

A

Donor Unit Testing

60
Q

Recently, the FDA provided guidance and recommended universal testing for the Zika virus.

A

Donor Unit Testing

61
Q
  1. Selection Criteria
A
62
Q

ABO antigens on the donor unit red blood cells must be compatible with the naturally occurring anti-A and/or anti-B in the recipient’s plasma.

A

ABO/Rh

63
Q

If whole blood is the only option, the product and the recipient must be ABO identical due to the plasma portion of the blood component.

A

ABO/Rh

64
Q

If a patient has a history of, or has detectable clinically significant antibodies, donor units selected for transfusion must be negative for the corresponding antigen(s).

A

Antigen-Negative

65
Q

AB

1st Choice:
2nd Choice:
3rd Choice:
4th Choice:

A

AB
A
B
O

66
Q

A

1st Choice:
2nd Choice:

A

A
O

67
Q

B

1st Choice:
2nd Choice:

A

B
O

68
Q

O

1st Choice:

A

O

69
Q

No compatibility testing is required for the transfusion of platelets, thawed plasma, and cryoprecipitate.

A

Platelets, Thawed Plasma, and Cryoprecipitate

70
Q

Either a current or a historical ABO grouping is sufficient.

A

Platelets, Thawed Plasma, and Cryoprecipitate

71
Q

Rh typing is ignored because these components contain very few red blood cells as a result of collection methods or frozen storage.

A

Platelets, Thawed Plasma, and Cryoprecipitate

72
Q

ABO-identical platelet units should be selected whenever possible to ensure adequate platelet survival.

A

Platelets, Thawed Plasma, and Cryoprecipitate

73
Q

Plasma units should be compatible with the recipient’s ABO red blood cell antigens.

A

Platelets, Thawed Plasma, and Cryoprecipitate